Haematological cancer: Feasible mutation-targeted therapy
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.108
Abstract: Approximately one-third of patients with acute myeloid leukaemia (AML) harbour mutations in FLT3, which encodes receptor-type tyrosine-protein kinase FLT3. Now, the therapeutic potential of the multikinase inhibitor midostaurin has been explored in this patient population… read more here.
Keywords: feasible mutation; mutation targeted; cancer feasible; targeted therapy ... See more keywords